Mutated KRAS is a genetic driver observed in nearly half of colorectal cancers and the vast majority of pancreatic cancers, making it an oncology holy grail target. In an early trial, a novel cancer vaccine that targets the resistant KRAS gene in human tumors has demonstrated promising long-term outcomes, as indicated by clinical data.

According to researchers from the University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, the vaccine, ELI-002 2P, has the potential to instruct the immune system to identify and combat tumors that contain mutant KRAS . In the AMPLIFY-201 trial ( NCT04853017 ), patients who had completed surgery and standard therapy but still showed signs of microscopic disease received the vaccine alone. The results, publishe

See Full Page